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ABSTRACT

ARTICLE HISTORY

Introduction: Myasthenia gravis (MG) is an antibody-mediated disease that develops in the majority of
patients mainly as a result of acetylcholine receptor (AChR) autoantibodies. This process is mediated by
a series of immunoregulatory events. Therapeutic targets for MG include suppression of circulating
antibodies or antibody production, suppression of complement activation, and immunomodulation of
cytokines or T cells. Intravenous immunoglobulin (IVIg) has an effect on all of these mechanisms.
Areas covered: This narrative review explores the broad immunomodulatory effects of IVIg in MG and
provides an update on IVIg treatment for MG.
Expert opinion: IVIg has a range of immunomodulatory effects on therapeutic targets relevant to the
immunopathogenesis of MG. An emerging area of research is the pharmacogenomics of IVIg in MG
related to FcRn and IgG catabolism. New data suggest that the FcRn VNTR3 genotype can affect the
efficacy of IVIg in certain MG patients and may have an impact on IgG kinetics and selected dosing.
Immune globulin 10% caprylate/chromatography purified (IVIg-C) has been shown to reverse the
symptoms of severe acute exacerbation in patients with MG supporting its use for this severely ill
subgroup of patients during a relapse.
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1. Introduction
Myasthenia gravis (MG) is a prototypic antibody-mediated
disease that, in the majority of cases, occurs due to develop
ment of autoantibodies against acetylcholine receptors
(AChR). The antibodies block AChR-binding sites at the endplate region; they cross-link and internalize the receptors, and
initiate the membrane attack complex via complement activa
tion, thereby destroying AChRs at the end-plate region of the
neuromuscular junction.
This process is mediated by a series of immunoregulatory
events. The main immune factors involved in the pathogenesis
of MG include: antibodies against AChR; B cells and B cell
trophic factors; complement, which fixes antibodies at the
end-plate region; CD4 + T cells and associated cytokines,
which facilitate antibody production by B cells and plasma
cells; regulatory T cells (Treg) and T helper cells (e.g. Th17+)
that affect antibody production via Th1/Th2 cytokine balance;
and cytokines, such as interleukin (IL)-6, that affect the induc
tion of Treg to pathogenic Th1 (anti-IL6 suppresses experi
mental autoimmune MG [EAMG]) [1].
Therapeutic targets for MG include suppression of circulat
ing antibodies or antibody production, suppression of com
plement activation, and immunomodulation of cytokines or
T cells. Intravenous immunoglobulin (IVIg) has effects on all
these mechanisms.
This narrative review, which is based on proceedings of
a symposium held in May 2021 during the 16th
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International Congress on Neuromuscular Diseases
(ICNMD 2021) virtual congress, explores the broad immu
nomodulatory effects of IVIg in MG and provides an
update on IVIg treatment for MG.

2. Intravenous immunoglobulin in myasthenia
gravis
IVIg works by multiple mechanisms that restore immune bal
ance. Main factors involved the pathogenesis of MG that are
relevant to the immunomodulatory actions of IVIg include
antibodies, complement, cytokines, FcγRIIb, T cells and anti
gen-presenting cells (APC), and immunoregulatory genes [2].

2.1. Effect of IVIg on antibodies
IVIg affects antibodies in several ways (Figure 1) [2]. First, IVIg
provides idiotypic antibodies that can neutralize pathogenic
autoantibodies. Immunoglobulins have idiotypes which can
form monomers or dimers. Because IVIg is derived from thou
sands of donors, up to 40% of the immunoglobulins in IVIg are
in dimeric pairs. These idiotypes form dimers with circulating
pathogenic autoantibodies, leading to destruction of some
pathogenic antibodies.
Second, IVIg can affect B-cell trophic factors such as B-cell
activating factor (BAFF) and its close relative APRIL (A
Proliferation-Inducing Ligand) [3]. BAFF is known to be

CONTACT Marinos C Dalakas
marinos.dalakas@jefferson.edu
Department of Neurology, Thomas Jefferson University, 901 Walnut Street, Philadelphia,
Pennsylvania, PA 19107, USA; Neuroimmunology Unit, National and Kapodistrian University of Athens, Athens, Greece
© 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/),
which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.

314

M. C. DALAKAS AND A. MEISEL

2.2. Effect of IVIg on complement
Article highlights
●

●

●

Intravenous immunoglobulin (IVIg) has a range of immunomodula
tory effects on relevant therapeutic targets for myasthenia gravis
(MG), such as suppression of circulating antibodies or antibody
production, suppression of complement activation, and immunomo
dulation of cytokines or T cells.
An emerging area of research is the pharmacogenomics of IVIg in
MG. It has recently been shown that polymorphisms in the VNTR3
gene that encodes the FcRn receptor can affect IVIg kinetics and
patient outcomes.
A phase 3 clinical trial showed that immune globulin (human) 10%
caprylate/chromatography purified (IVIg-C) reversed the symptoms of
severe acute exacerbation in patients with MG and was well toler
ated. Clinically meaningful improvements in efficacy measures were
seen as early as day 7 and continued to the end of the study (day 28).

increased in patients with MG, and can be suppressed by
IVIg [4].
Third, IVIg can saturate FcRn transport receptors leading
to accelerated catabolism of pathogenic immunoglobulin
G (IgG), thus reducing circulating antibody titers. FcRn is
found on the surface of many cells and is involved in the
recycling of IgG through endosomes and back into the
circulation [5]. Upon saturation of FcRn receptors by infused
IVIg, excess immunoglobulin, including anti-AChR autoanti
bodies will be transferred to lysosomes for degradation,
rather than being recycled into the circulation. In an experi
mental model of MG (EAMG), levels of all IgG types
decreased after IVIg infusion. Over the subsequent weeks,
a significant reduction in mean clinical score was seen
compared with control animals, with evidence of a doserelated effect [3].

Complement is bound by pathogenic antibodies in the endplate
region (Figure 1) [2]. In MG, complement C3b is increased, with
one study finding a geometric mean uptake value for C3 of
10,570 counts/minute in patients compared with 3459 in healthy
individuals [6]. The complement activation pathway leads to the
formation of the C3a and C3b products, which are then involved
in the formation of the membranolytic attack complex (MAC),
which leads to lysis of target cells.
IVIg can suppress the complement activation process by
suppressing C3a and C3b, thereby interfering with the forma
tion of MAC. IVIg has been shown to have a marked effect on
inhibition of complement consumption from 2 days after
infusion in patients with dermatomyositis, with C3b and
MAC deposits disappearing from muscle biopsy samples
after therapy [7]. Microvasculopathy and perifascicular atrophy
due to complement were reversed after complement inhibi
tion by IVIg, leading to neovascularization and restoration of
the muscle fiber architecture, which correlated with clinical
improvement. The effect of IVIg on C3 is dose-dependent.

2.3. Effect of IVIg on cytokines
IVIg has effects on various cytokines (Figure 1) [2]. In the EMAG
model, IVIg downregulated pro-inflammatory cytokines such
as tumor necrosis factor-alpha (TNFα), and upregulated antiinflammatory cytokines such as IL-4 and IL-10 [3]. IVIg also has
an effect on IL-1; in vitro research showed that IL-1 caused
destruction of cultured human myotubes, which were rescued
by the addition of IVIg (Dalakas MC unpublished data 1998)

Figure 1. Main factors involved in the immunopathogenesis of myasthenia gravis that are relevant to the actions of intravenous immunoglobulin. Reproduced with
permission from [2]. IVIg has effects on antibodies (1a,b,c,d), complement (2), cytokines (3a,b), FcγRIIB (4), and T-cell and APC functions (5a,b). It affects antibodies by
providing idiotypic antibodies, facilitating neutralization of pathogenic autoantibodies (1a), by affecting related cytokines (1b), by suppressing B-cell trophic factors,
such as B-cell activating factor (BAFF) (1c), and by accelerating the catabolism of pathogenic immunoglobulin G (IgG) by saturating the FcRn transport receptors
(1d). IVIg also: inhibits complement binding (2) and prevents membranolytic attack complex (MAC) formation; suppresses pathogenic cytokines (3a,b); upregulates
FcγRIIb inhibitory receptors (4), intercepting antibody-dependent cell-mediated cytotoxicity; has effects on antigen presenting cells, T-cell modulatory functions and
antigen recognition (5a,b); and affects immunoregulatory genes. AChR, acetylcholine receptor; APC, antigen-presenting cell; BAFF, B-cell activating factor; IL,
interleukin; MHC, major histocompatibility complex; TCR, T-cell receptor; Treg, regulatory T cell.
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2.4. Effect of IVIg on FcγRIIb
FcγRIIb inhibitory receptors are found on B cells and macro
phages. FcγRIIb on B cells transduce inhibitory signals on the
B cells and prevent their transformation into IgG-producing
plasma cells. Mice that lack FcγRIIb inhibitory receptors are
known to develop autoimmune diseases.
IVIg upregulates FcγRIIb inhibitory receptors, which inter
cepts antibody-dependent cell-mediated cytotoxicity, and
enhances its therapeutic efficacy. This has been shown in
chronic inflammatory demyelinating polyneuropathy (CIDP)
[8]. Patients with active CIDP have decreased FcγRIIb inhibitory
receptors in memory B cells and monocytes. Administration of
IVIg leads to upregulation of FcγRIIb in monocytes, naïve and
memory B cells, which correlates with clinical benefit. The
same process can be assumed in MG and other autoimmune
diseases.

2.5. Effect of IVIg on T-cell and APC function
IVIg has effects on various T-cell factors and co-stimulatory
molecules. In the EAMG model, IVIg-induced reduction in the
co-stimulatory molecule CD40 ligand in treated animals com
pared with controls correlated with clinical benefit [3]. MHC
class 1 is upregulated in muscle biopsies from patients with
inflammatory myopathies but is substantially downregulated
after IVIg administration.
Preliminary data have suggested that a subset of Treg cells
associated with cytotoxic T lymphocyte-associated antigen-4
(CTLA-4) is functionally defective in patients with MG, but after
IVIg therapy these cells were expanded, suggesting that IVIg
may also affect the function of Tregs [9].

2.6. Pharmacogenomics of IVIg in MG
The pharmacogenomics of IVIg in MG is a novel area of
research which may have important implications. IVIg is
known to be highly effective in some patients, but not in
others with clinically similar disease states. It is possible that
various biologically relevant genes that are modulated by IVIg
directly at the respective tissues may play a role in this
variation.
There are data indicating that polymorphisms in the VNTR3
gene that encodes the FcRn receptor can affect IVIg kinetics and
patient outcomes [5,10]. Individuals who are homozygous for
VNTR3 (i.e. VNTR3/3), the most common allele, have increased
FcRn function. Patients who have heterozygous VNTR2/3 geno
types have reduced FcRn saturation, meaning that less IVIg is
returned to the circulation and more is sent to the lysosomes,
which results in enhanced catabolism of infused IVIg and lower
serum IgG levels. Patients with MG who were homozygous for
VNTR3 had higher IgG concentrations after IVIg infusion and
were more likely to be responders compared with those who
were heterozygous [9]. This suggests that VNTR3 genotype mat
ters with respect to the efficacy of IVIg in MG. It is possible that
the VNTR2/3 genotype could serve as a predictive marker for
a poor response to IVIg in some MG patients.
VNTR3 gene polymorphisms may also explain the lack of
response in 20–30% of patients treated with IVIg, which is
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relevant not only in MG but also in other disorders such as
CIDP, Guillain–Barré syndrome and multifocal motor neuropa
thy. Patients who are heterozygous for VNTR3 are likely to
require higher IVIg doses (such as super-high IVIg at 3–4 g/
kg per month) or more frequent administrations if 2 g/kg is
not effective. This warrants further study in the future.

3. New clinical data on IVIg treatment of MG
3.1. Clinical presentation of MG
Half of patients with MG have ocular onset, with symptoms
such as diplopia and ptosis [11–13]. Of these, 50–70% progress
to generalized MG [11]. A generalized onset is seen in 40% of
patients. Muscle fatigability is the key feature of MG [12,13].
Many patients have pronounced facial muscle involvement.
The muscle weakness in the extremities tends to affect more
the proximal than the distal muscle groups [12]. The maximum
severity of MG is usually reached within 3 years from onset in
80–90% of patients [13].
The Myasthenia Gravis Foundation of America (MGFA) clin
ical classification can be summarized as follows: Class I covers
pure ocular muscle weakness; Classes II–IV cover different
severities of muscle weakness (from mild to severe), with
subclasses based on whether the weakness predominantly
affects (a) limb/axial muscles or (b) oropharyngeal/respiratory
muscles; and Class V is myasthenic crisis, defined by the need
for intubation [14].

3.2. Exacerbation of MG and myasthenic crisis
Clinical red flags for MG exacerbation and crisis include: febrile
bacterial infections within the last 2 weeks (this can trigger MG
and may be associated with a more severe disease course);
inverse aspiration of food and drink into the nose when
swallowing; inadequate swallowing (causing coughing or
throat clearing); aphonic dysarthria (increasing phonation
weakness with hypernasal speech); dropped head (head tips
forward due to fixed paresis of the head extensor muscles);
dropped chin (i.e. the lower jaw drops after extended chew
ing); and, most importantly, a reduced vital capacity to
<1500 mL (men)/<1000 mL (women) or estimated 20 mL/kg
bodyweight [15,16]. The dynamics of a change in vital capacity
is also important, with a rapid decrease (over a matter of days)
posing the greatest concern.

3.3. Treatment of MG
Standard symptomatic treatment of MG is pyridostigmine,
usually with the addition of corticosteroids (or steroidsparing immunosuppressive therapy) in the case of moderate
severity disease [17]. With increasing disease severity, treat
ment escalation to include IVIg, plasmapheresis or immunoad
sorption therapies may be indicated. An exacerbation may
necessitate intensive care [18].
All patients diagnosed with MG should be screened for
thymoma; if found, the patient should undergo thymectomy.
If a thymoma is not identified by computed tomography,
AChR antibody–positive patients, aged 18–60 years, with
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generalized disease and a disease course of <5 years may be
considered for thymectomy as immunosuppressive-sparing
treatment [19,20].
The latency period until an effect is observed varies accord
ing to type of therapy. Pyridostigmine can produce an effect
within hours, whereas corticosteroids take 3–4 weeks, and
extended therapy with steroid-sparing treatments can take
2–18 months. For example, azathioprine generally takes 12–
18 months to produce an adequate effect in terms of stabiliz
ing the patient’s condition. Eculizumab is now available as an
option for AChR antibody-positive patients with treatmentrefractory MG, and takes 3–4 weeks to produce an effect [21].
Treatments used for exacerbations or myasthenic crisis,
such as IVIg, plasmapheresis and immunoadsorption thera
pies, are faster acting, producing an effect within a few days
to a couple of weeks [18].

3.4. Clinical trial of IVIg-C in subjects with severe acute
MG exacerbations
The efficacy and safety of immune globulin (human) 10%
caprylate/chromatography purified (IVIg-C) (Gamunex®-C,
Grifols Inc., Clayton, NC, USA) were evaluated in a study of
patients with MG exacerbations [22]. This phase 3, multicenter,
prospective, open-label, non-controlled clinical trial was con
ducted in 15 centers in 10 countries. Participants received
a 2 g/kg bodyweight infusion of IVIg-C administered as
a 1 g/kg/day dose over 2 consecutive days. Key outcome
measures were the Quantitative Myasthenia Gravis (QMG)
test score, the Myasthenia Gravis composite (MG Composite)
score, and the Myasthenia Gravis Activities of Daily Living (MGADL) profile.
The study included patients aged ≥18 years who had MG
exacerbation, defined as worsening of symptoms with MGFA
classification IVb or V; i.e. affecting the respiratory muscles,
while receiving long-term (≥8 weeks) corticosteroid treatment

for MG. Key exclusion criteria were: treatment with IVIg or
plasmapheresis within 30 days, modification of corticosteroid
treatment within the previous 2 weeks, positivity for antiMuSK antibodies, or MG exacerbation attributable to
a change in medication or an infection (with fever, positive
blood culture, leukocytosis, or pulmonary infiltrates on x-ray).
The primary efficacy endpoint was the change in QMG
score from baseline to day 14. Secondary endpoints included
the percentage of participants with clinical improvement from
baseline to day 14 (QMG decrease ≥3 points; MG Composite
decrease ≥3 points; MG-ADL decrease ≥2 points). Change from
baseline and percentage of participants with clinical improve
ment in QMG, MG Composite, and MG-ADL at other time
points (days 7, 21 and 28) were evaluated as exploratory
endpoints. Safety measures included laboratory parameters
and evaluation of adverse events. Changes in routine MG
therapy were not permitted until after the primary endpoint
assessment on day 14 (unless required for safety reasons).
Among 49 enrolled patients, 43 were evaluable for efficacy.
The majority of participants (69.4%) were female, and median
age was 47 years. All patients were MGFA Class IVb at enroll
ment, with a median time since initial MG diagnosis of
5.4 years. Overall, 59% of enrolled patients had a history of
a positive AChR antibody test; amongst the efficacy-evaluable
population, 32 (74%) were AChR antibody-positive at baseline
and 11 (26%) were AChR antibody-negative. Patients had sig
nificant weakness, with mean baseline scores of 22.0 ± 4.60
points for QMG, 28.9 ± 6.80 points for MG Composite, and
13.8 ± 3.96 points for MG-ADL.
At day 14, there was a significant decrease from baseline in
mean QMG score (primary endpoint) of – 6.4 ± 5.2 points (95%
confidence interval – 7.96 to – 4.79, p < 0.001); Figure 2 [22],
indicative of clinically meaningful improvement (decrease of
≥3 points). Improvement was evident by day 7, and was even
more pronounced at days 21 and 28. Subjects with positive or
negative baseline AChR levels responded similarly to IVIg-C

Figure 2. Efficacy of IVIg-C in patients with exacerbation of myasthenia gravis: change in Quantitative Myasthenia Gravis (QMG) score from baseline to day 14. Data
from [22]. IVIg-C = immune globulin caprylate/chromatography purified.
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receptor can affect IVIg kinetics and patient outcomes, which
may explain at least in part the lower responsiveness of some
patients to IVIg.
Fatigability is the central clinical feature of MG. Standard
initial treatment is pyridostigmine, often with the addition of
corticosteroids. As disease severity progresses, treatment is
escalated to include IVIg, plasmapheresis or immunoadsorp
tion therapies. A multicentre, prospective, open-label, noncontrolled clinical trial of IVIg-C showed that it reversed the
symptoms of severe acute exacerbation in patients with MG.
Clinically meaningful improvements were observed for effi
cacy outcome measures as early as day 7, and continued to
study end (day 28). There was a significant decrease in QMG
at day 14 (primary endpoint) and high response rates were
recorded for other outcome measures at this timepoint. Safety
outcomes supported the well-established safety profile of IVIgC in patients with severe acute exacerbations of MG.

Figure 3. Efficacy of IVIg-C in patients with exacerbation of myasthenia gravis:
percentage of participants with a clinical improvement from baseline to day 14
(QMG decrease ≥3 points; MG Composite decrease ≥3 points; MG ADL decrease
≥2 points). Data from [22]. IVIg-C = immune globulin caprylate/chromatography
purified; MG-ADL = Myasthenia Gravis Activities of Daily Living profile; MG
Composite = Myasthenia Gravis composite; QMG = Quantitative Myasthenia
Gravis score.

treatment, and both achieved statistically significant improve
ments in the QMG score at Day 14. Improvements over time
were observed for MG Composite and MG-ADL scores, with
mean decreases of – 12.1 ± 7.7 and – 6.2 ± 3.9 points,
respectively, recorded at day 14. The majority of patients
experienced a clinically meaningful improvement in QMG,
MG Composite and MG-ADL scores at day 14 (secondary end
points; Figure 3) [22].
Overall, 80% of patients experienced a treatment-emergent
adverse event (TEAE). Most TEAEs were mild or moderate in
severity. There were no serious adverse events and no throm
boembolic events. The most frequent TEAEs were headache
(38.8%) and pyrexia (16.3%), followed by urticaria (8.2%) and
influenza-like illness, rash and vomiting (each 6.1%). Three
participants discontinued treatment after receiving IVIg-C
because of mild or moderate adverse events; these events
resolved within 1 day [22].

4. Conclusion
IVIg works by multiple mechanisms that restore immune bal
ance, many of which are relevant for its effects in patients with
MG. IVIg affects antibodies by providing idiotypic antibodies
and potential neutralization of pathogenic autoantibodies, by
accelerating the catabolism of pathogenic IgG through satura
tion of the FcRn transport receptors, and by suppressing B-cell
trophic factors such as BAFF. Other effects include: inhibition
of complement binding and prevention of MAC formation;
suppression of pathogenic cytokines; upregulation of FcγRIIb
inhibitory receptors, which intercepts antibody-dependent
cell-mediated cytotoxicity; effects on APCs, T-cell modulatory
functions and antigen recognition. Recent evidence suggests
that polymorphisms in the VNTR3 gene that encodes the FcRn

5. Expert opinion
The pathogenesis of MG is mediated by various immunoregu
latory events. IVIg has a range of immunomodulatory effects
on relevant therapeutic targets for MG, such as suppression of
circulating antibodies or antibody production, suppression of
complement activation, and immunomodulation of cytokines
or T cells. An emerging area of research is the pharmacoge
nomics of IVIg in MG. Recent data indicating that VNTR3
genotype can affect the efficacy of IVIg in patients with MG
are interesting. The potential for VNTR2/3 genotype to act as
a predictive marker for a poor response to IVIg in patients
with MG, and the best approach to dose modification in
these patients, require further study. Additional data on the
role of pharmacogenomics in MG is likely to emerge in the
coming years.
Plasmapheresis and IVIg are fast-acting therapies that are
used to treat exacerbations and myasthenic crisis. Results of
a phase 3 study provide evidence of the efficacy and safety of
IVIg-C for treatment of severe acute exacerbations of MG. The
magnitude of the treatment effect was impactful and clini
cally significant and consistent with improvements reported
in randomized controlled clinical trials of IVIg in worsening
MG/MG exacerbations.
Patients who experience exacerbations or myasthenic crisis
despite ongoing immunosuppressive treatment may require
escalation of therapy. Rituximab, a monoclonal antibody tar
geting B cells, is one option. However, most data on its use in
MG come from uncontrolled studies, and a placebo-controlled
study did not meet the primary endpoint mostly related to
study design [23]. Considering the impressive clinical benefit
reported with rituximab in uncontrolled series, additional stu
dies to clarify how many cycles of rituximab are required to
achieve treatment success and determination of biomarkers to
help identify patients who would benefit from such treatment
are needed. Eculizumab, a monoclonal antibody directed
against complement has been approved for the treatment of
generalized AChR+ MG [21] and other anti-complement
agents are in the offing. Several other biologic agents, includ
ing agents directed against B cells and the FcRn receptor are
currently being evaluated [2]. Efgartigimod, an FcRn inhibitor,
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was recently approved by the FDA for the treatment of gen
eralized MG [24] and other FcRn inhibitors are in Phase II–III
clinical trials. It is hoped that in the near future additional
targeted immunotherapies will be available for the treatment
of patients with MG, including those with refractory disease,
and this will likely change the therapeutic algorithm.
IVIg is effective for treating acute exacerbations by provid
ing immediate relief. However, it is often used as maintenance
therapy, although its long-term efficacy has not been estab
lished [2]. Clinical trials to formally evaluate the efficacy of IVIg
in the long-term management of MG and as a steroid-sparing
therapy have now been completed, but have not yet been
reported (ClinicalTrials.gov: NCT 02473952; NCT 02473965).
Considering that MG is a chronic autoimmune disease the
results of these studies will add to the knowledge about the
role of IVIg in the long-term management of MG.
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